Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
在至少接受过两种TKI治疗的无BCR::ABL1 T315I突变的慢性粒细胞白血病慢性期（CML-CP）患者中，Asciminib单药治疗：4年I期安全性和有效性结果
期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-023-01860-w
Mauro, Michael J; Hughes, Timothy P; Kim, Dong-Wook; Rea, Delphine; Cortes, Jorge E; Hochhaus, Andreas; Sasaki, Koji; Breccia, Massimo; Talpaz, Moshe; Ottmann, Oliver; Minami, Hironobu; Goh, Yeow Tee; DeAngelo, Daniel J; Heinrich, Michael C; Gómez-García de Soria, Valle; le Coutre, Philipp; Mahon, Francois-Xavier; Janssen, Jeroen J W M; Deininger, Michael; Shanmuganathan, Naranie; Geyer, Mark B; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Hoch, Matthias; Lang, Fabian
